Click here to download Javelin's Annual Report for 2008
News:
March 9, 2010 Javelin Pharmaceuticals Reports Fiscal Results for the Year Ended 2009
February 17, 2010 Javelin Pharmaceuticals' Receives FDA PDUFA Date for Dyloject™ NDA February 11, 2010 Third Party Reexamination of Javelin Pharmaceuticals' Phase III Trial Data for Ereska™ (Intranasal Ketamine) Yields Statistically Significant Primary Endpoint
February 2, 2010 FDA Accepts Javelin Pharmaceuticals' Dyloject™ New Drug Application for Formal Review
December 18, 2009 Myriad Pharmaceuticals to Acquire Javelin Pharmaceuticals Click Here for the Webcast (Registration Required)
December 2, 2009 Javelin Pharmaceuticals Submits Dyloject™ New Drug Application to FDA for Management of Acute Moderate-to-Severe Pain in Adults
November 10, 2009 Javelin Pharmaceuticals, Inc. Reports Third Quarter 2009 Results November 4, 2009 Javelin to Announce Third Quarter Results Click here for the webcast (Registration Required)
CONTACT US JOIN US SITE MAP © 2005-2010 Javelin Pharmaceuticals,Inc. / Intrac,Inc. /IDDS,Inc. All rights reserved. All other trademarks are the properties of their respective owners. Reproduction in whole or in part in any form or medium without express written permission of Javelin Pharmaceuticals,Inc. / Intrac,Inc. /IDDS,Inc. is prohibited.
Read
more
